Sponsor

Intergroupe Francophone de Cancerologie Thoracique

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Intergroupe Francophone de Cancerologie Thoracique appears in 60 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials60
Recruiting shown7
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaNCT07234058 · lead sponsor · 2026-04-02
RECRUITING
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)NCT06937905 · lead sponsor · 2026-02-06
RECRUITING
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedNCT06908993 · lead sponsor · 2025-12-09
RECRUITING
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerNCT06656598 · lead sponsor · 2025-11-07
RECRUITING
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyNCT06840834 · lead sponsor · 2025-06-30
RECRUITING
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)NCT06053099 · lead sponsor · 2024-01-22
RECRUITING
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy InductionNCT05255302 · lead sponsor · 2022-05-02
RECRUITING
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung CancerNCT07759492 · lead sponsor · 2026-11-01
NOT_YET_RECRUITING
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNCT07420439 · lead sponsor · 2026-09-15
NOT_YET_RECRUITING
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)NCT05856695 · lead sponsor · 2023-11-17
ACTIVE_NOT_RECRUITING
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & ChemotherapyNCT05781308 · lead sponsor · 2023-04-26
ACTIVE_NOT_RECRUITING
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)NCT05200481 · lead sponsor · 2022-05-18
ACTIVE_NOT_RECRUITING
RW Effectiveness of Lurbinectedin in Extensive Stage SCLCNCT05285033 · lead sponsor · 2022-04-01
COMPLETED
RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLCNCT05273047 · lead sponsor · 2022-03-01
UNKNOWN
RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)NCT05154344 · lead sponsor · 2021-11-29
COMPLETED
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)NCT04621188 · lead sponsor · 2021-03-19
ACTIVE_NOT_RECRUITING
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective EvaluationNCT04775095 · lead sponsor · 2021-03-08
COMPLETED
Atezolizumab Combined With Chemotherapy in Extensive Stage SCLCNCT04920981 · lead sponsor · 2021-02-02
COMPLETED
ENCOrafenib With Binimetinib in bRAF NSCLCNCT04526782 · lead sponsor · 2021-01-19
ACTIVE_NOT_RECRUITING
Immunotherapy in Patient With Poor General ConditionNCT04108026 · lead sponsor · 2020-10-14
COMPLETED
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerNCT04111705 · lead sponsor · 2020-08-05
COMPLETED
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationNCT04233021 · lead sponsor · 2020-07-16
COMPLETED
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel ChemotherapyNCT03977194 · lead sponsor · 2019-07-23
ACTIVE_NOT_RECRUITING
Her2-positive Lung Cancer Treated With Dedicated DrugNCT03845270 · lead sponsor · 2019-05-17
COMPLETED
Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving LorlatinibNCT03727477 · lead sponsor · 2019-02-01
COMPLETED
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)NCT03591731 · lead sponsor · 2019-01-02
COMPLETED
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErNCT03469960 · lead sponsor · 2018-05-02
COMPLETED
Immunotherapy by Nivolumab for HIV+ PatientsNCT03304093 · lead sponsor · 2017-10-19
COMPLETED
Immunotherapy as Second-line in Patient With Small Cell Lung CancerNCT03059667 · lead sponsor · 2017-03-13
COMPLETED
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung CancerNCT03030131 · lead sponsor · 2017-01-12
TERMINATED
Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU ProgramNCT02933346 · lead sponsor · 2016-09-01
COMPLETED
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerNCT02716311 · lead sponsor · 2016-05-01
COMPLETED
Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK RearrangementsNCT02727335 · lead sponsor · 2014-05-01
COMPLETED
Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung CancerNCT01850303 · lead sponsor · 2013-05-16
COMPLETED
Paclitaxel-bevacizumab in Advanced Lung CancerNCT01763671 · lead sponsor · 2013-05-01
COMPLETED
Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.NCT01705184 · lead sponsor · 2012-12-01
COMPLETED
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung CancerNCT01631136 · lead sponsor · 2012-07-01
COMPLETED
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRNCT01556191 · lead sponsor · 2012-05-15
COMPLETED
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular TestingsNCT01700582 · lead sponsor · 2012-04-01
COMPLETED
French Biological Observatory on Lung Cancer in Never SmokersNCT01465854 · lead sponsor · 2011-11-01
COMPLETED
Chemotherapy for Lung Cancer in HIV-positive PatientsNCT01296113 · lead sponsor · 2011-05-01
COMPLETED
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)NCT01102231 · lead sponsor · 2010-03-01
COMPLETED
Bevacizumab in Extensive Small Cell Lung CancerNCT00930891 · lead sponsor · 2009-09-01
COMPLETED
TAilored Post-Surgical Therapy in Early Stage NSCLCNCT00775385 · lead sponsor · 2009-04-01
COMPLETED
Adjuvant Pazopanib in Stage I NSCLCNCT00775307 · lead sponsor · 2008-11-01
COMPLETED
NSCLC Relapse Therapy After Surgery and Peri-operative ChemotherapyNCT00535275 · lead sponsor · 2007-09-01
TERMINATED
Therapeutic Strategy in Advanced Bronchioloalveolar CarcinomaNCT00384826 · lead sponsor · 2006-09-01
COMPLETED
Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)NCT00298415 · lead sponsor · 2006-03-01
COMPLETED
Treatment of Lung Adenocarcinoma With Bronchioloalveolar FeatureNCT00198380 · lead sponsor · 2005-04-01
COMPLETED
Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-upNCT00198341 · lead sponsor · 2005-01-01
COMPLETED
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IVNCT00198393 · lead sponsor · 2004-11-01
COMPLETED
A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.NCT00198406 · lead sponsor · 2002-09-01
COMPLETED
Chemoradiotherapy of NSCLC Stage IIIBNCT00198432 · lead sponsor · 2002-03-01
COMPLETED
Stage I/II NSCLC Perioperative ChemotherapyNCT00198354 · lead sponsor · 2001-05-01
COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseNCT02046733 · collaborator · 2015-12-18
COMPLETED
Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLCNCT02473133 · collaborator · 2015-11-12
COMPLETED
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · collaborator · 2015-02-24
COMPLETED
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsNCT02117167 · collaborator · 2014-04-23
COMPLETED
Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung CancerNCT00433563 · collaborator · 2008-04-01
COMPLETED
Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by SurgeryNCT00410683 · collaborator · 2007-02-01
UNKNOWN

Sponsor roles

lead sponsor54
collaborator6
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.